November 16, 2015

Biocept to Present Data Demonstrating a High Correlation of Biomarker Detection from its Liquid Biopsy Assays and Tissue Samples at the SelectBIO Biofluid Biopsies & High-Value Diagnostics 2015 Meeting

SAN DIEGO, Nov. 16, 2015 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of patients with cancer, today announced the presentation of recent analytical and clinical results demonstrating a high correlation between its liquid biopsy assays and surgical tissue samples for a range of biomarkers and different solid tumor types using circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). These findings will be discussed in a presentation entitled, "Use of ctDNA and CTCs in the Biomarker Identification and Monitoring of Patients with Cancer," at the SELECTBIO meeting on Biofluid Biopsies & High-Value Diagnostics 2015 on November 16th in Boston.

"Liquid biopsies are increasingly becoming recognized as an important sample type in the testing of patients with solid tumors," said Veena Singh, MD, Senior Vice President and Senior Medical Director at Biocept. "Tumor material in the form of CTCs and ctDNA is shed in the vasculature from both primary and metastatic sites. Our ability to capture and analyze both sources of tumor material at a very high level of sensitivity can provide highly valuable information about the tumor at the time of diagnosis, as well as at progression or for monitoring, of cancer patients in a safer, real-time and cost-effective manner."

"Meetings dedicated exclusively to liquid biopsies, like the one organized by SELECTBio in Boston, are indicative of the recognized importance of this sample type for acquiring information to inform treatment of patients with solid tumors," said Lyle Arnold, PhD, Senior Vice President and Chief Scientific Officer. "I am delighted to be sharing our unique technology and our recent significant analytical and clinical results with attendees at this meeting."

As part of the presentation, Dr. Arnold will review Biocept's ability to perform comprehensive molecular profiling to benefit cancer patients using DNA found in blood as a sample type rather than tissue obtained through a surgical biopsy procedure. The presentation will highlight Biocept's broad menu of testing in a wide variety of tumor types, as well as the concordance and sensitivity data generated through extensive analytical and clinical validation studies.

Biocept has a number of ongoing studies to demonstrate the performance and clinical utility of its liquid biopsy platform. These studies focus on the detection of key predictive biomarkers in blood for therapy selection when surgical tissue biopsies are inadequate and for serially monitoring the presence and concentrations of these biomarkers throughout therapy.

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated tests for other solid tumors in the near term. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations

and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to physician adoption of liquid biopsy, and our ability to further enhance our product portfolio, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at www.sec.gov.

Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO